Lonza buys Dutch cell and gene therapy CMO

Visp, Switzerland-based Lonza has acquired Dutch gene and cell contract therapy manufacturer PharmaCell because of its expertise with autologous cell and gene therapy manufacturing.

Even as CDMO Lonza deals with FDA concerns about its cell manufacturing operation in the U.S., it has gone out and acquired a gene and cell contract manufacturer in Europe.

Lonza said last week that it had acquired Netherlands-based PharmaCell for an undisclosed sum. It said the company had revenues of about €11 million last year. The company has a 15,500 cell manufacturing facility in Maastricht, The Netherlands, which can produce clinical through commercial-scale product.

Lonza said PharmaCell was primarily selected because of its expertise in autologous cell and gene therapy manufacturing, which includes experience with two licensed products in Europe.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

"PharmaCell’s position in the market complements Lonza’s leadership position in the allogeneic cell manufacturing market," Andreas Weiler, head of emerging technologies at Lonza said in a statement.

Autologous therapies use a patient’s own cells to create custom products as opposed to allogeneic therapies which can be manufactured in large batches from unrelated donor tissues such as bone marrow which can be used in “off-the-shelf” therapies.

Loza said with this deal its gene therapy manufacturing network will span Europe, Asia and the U.S. It is Lonza’s U.S. operation in the U.S. that recently ran into FDA concerns. Lonza had its cell therapy facility in Walkersville, Maryland, slapped with a warning letter in April after earlier halting some production of liquid media products being produced for a client.

The plant is overseen by the FDA’s devices unit because its products are used for diagnostics. The letter said that retained samples were found to have Pantoea organisms that Lonza discovered after receiving two confirmed complaints for sterility failures of a of product.

A spokesperson said when the warning letter was issued that the company expects to have the problems resolved and FFM media manufacturing back online by mid-2017. The company had already begun a $7.6 million manufacturing upgrade at the facility, which is slated to be finished in 2018.

Suggested Articles

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

United Airlines last week delivered the first doses of Pfizer's vaccine from Belgium to the U.S. as the drugmaker preps for a potential December nod.